High materiality7/10
Rapport Therapeutics initiated with a Buy at Guggenheim
Why it may matterVerify against the original reporting
bullish
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Rapport Therapeutics initiated with Buy by Guggenheim; target $65; posted price $32.19.
- Rapport Therapeutics Buy; Target $65; price $32.19; Guggenheim.
Key facts
- 01
Target: $65
- 02
Posted price: $32.19
- 03
Analyst firm: Guggenheim
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.